Carl Zeiss Meditec Invests in Sales Expansion in Spain

Acquisition of the surgical ophthalmology business assets of IMEX

27-Sep-2011 - Germany
Carl Zeiss Meditec AG announced its intention to acquire the intraocular lens (IOLs) and ophthalmic viscoelastic devices (OVDs) business of IMEX, Spain, to strengthen its sales, service and support network in Spain. This is the objective of an asset purchase agreement signed by both parties this evening in Vienna, Austria. Until now, IMEX has been the exclusive partner of Carl Zeiss Meditec for its IOL & OVD business on the Iberian peninsula. The transaction is expected to close by the end of 2011.
Carl Zeiss Meditec's growth strategy is to provide comprehensive product solutions and excellent services to its customers. "Merging the sales forces of IMEX and Carl Zeiss Meditec in Spain enables us to offer diagnostic and surgical equipment, as well as the IOLs and OVDs for surgical ophthalmology procedures, to our Iberian customers from a single source," explains Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG. With the joint sales forces, Carl Zeiss Meditec will be able to establish a very strong, competitive team of ophthalmic experts in the market. Carl Zeiss Meditec will maintain the outstanding level of service and support both organizations are known for. Dr. Monz continues: "This approach will result in less complexity for customers as they will need to deal with only one partner." In addition, Carl Zeiss Meditec expects to improve its business performance through the replacement of the indirect sales channel.
Spain has always been an important market for Carl Zeiss Meditec, especially for the surgical ophthalmology business that was very successfully developed and expanded to Portugal by IMEX in recent years. With this acquisition, Carl Zeiss Meditec is strengthening its business, particularly in Spain, and systematically investing in its sales and service organization. "This step will enhance our market penetration and support future growth," concludes Dr. Ludwin Monz.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances